Kardigan Inc. has priced an upsized biopharma IPO to raise about $400 million gross, following strong demand that pushed the deal to the top end of its range. The cardiovascular-focused company is selling 25 million shares at $16 per share. The transaction comes after Kardigan’s earlier IPO plans and reflects continuing investor appetite for new public listings tied to mid-stage clinical development programs. Company disclosures indicate three cardiovascular candidates in mid-stage development, with key data expected in 2027 that could shape potential Phase 3 plans. The IPO window remains active alongside other financings seen across the sector, as new entrants attempt to build cash runway into late-stage clinical catalysts.